May 28, 2014, 8:27 AM
- Hikma Pharmaceuticals (HKMPF) has agreed to buy the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300M, as it attempts to boost its "injected medicine" market share.
- The company will pay $225M upfront for the assets of Boehringer's Bedford Laboratories and another $75M over the course of five years based on the performance of the drugs.
Nov. 23, 2011, 1:59 PM
HKMPY vs. ETF Alternatives
Other News & PR